<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: We sought to establish the extent and mechanisms by which <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> and <z:chebi fb="0" ids="6801">metformin</z:chebi> singly and in combination modify islet disease progression in human islet amyloid <z:chebi fb="1" ids="15841">polypeptide</z:chebi> transgenic (HIP) rats, a model for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: HIP rats were treated with <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>, <z:chebi fb="0" ids="6801">metformin</z:chebi>, <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> plus <z:chebi fb="0" ids="6801">metformin</z:chebi>, or no drug as controls for 12 weeks </plain></SENT>
<SENT sid="2" pm="."><plain>Fasting blood <z:chebi fb="105" ids="17234">glucose</z:chebi>, insulin sensitivity, and beta-cell mass, function, and turnover were measured in each group </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: <z:chebi fb="0" ids="40237">Sitagliptin</z:chebi> plus <z:chebi fb="0" ids="6801">metformin</z:chebi> had synergistic effects to preserve beta-cell mass in HIP rats </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> more than <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> inhibited beta-cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> enhanced hepatic insulin sensitivity; <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> enhanced extrahepatic insulin sensitivity with a synergistic effect in combination </plain></SENT>
<SENT sid="6" pm="."><plain>beta-Cell function was partially preserved by <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> plus <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>However, <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> treatment was associated with increased pancreatic ductal turnover, ductal <z:mpath ids='MPATH_160'>metaplasia</z:mpath>, and, in one rat, <z:hpo ids='HP_0001733'>pancreatitis</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: The combination of <z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> had synergistic actions to preserve beta-cell mass and function and enhance insulin sensitivity in the HIP rat model of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>However, adverse actions of <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> treatment on exocrine pancreas raise concerns that require further evaluation </plain></SENT>
</text></document>